RotationRx · Drugs · Scores · Protocols · Diagnoses · Specialties

← Drug Reference

Risperidone

Schizophrenia, Acute manic or mixed episodes associated with Bipolar I Disorder, Irritability associated with autistic disorder

Boxed warning

  • WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of patients with dementia-related psychosis. [see Warnings and Precautions ( 5.1 )] WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis ... (see full label)

Indications

  • Schizophrenia
  • Acute manic or mixed episodes associated with Bipolar I Disorder
  • Irritability associated with autistic disorder

Adult dosing

  • schizophrenia: dose: 2; unit: mg; route: PO; interval: per day (once or twice daily); titrate by 1-2 mg/day; target 4-8 mg/day; fixed: true; labelExcerpt: Initial dosing is 2 mg per day

Pediatric dosing

  • Consult pharmacy/current label

Renal adjustment

  • severe: 0.5 mg twice daily; note: For severe renal impairment (Clcr < 30 mL/min), initial dose 0.5 mg BID; titrate at intervals of 1 week or greater. Label: "For patients with severe renal impairment (Clcr< 30 mL/min) or hepatic impairment (10-15 points on Child Pugh System), the initial starting dose is 0.5 mg twice daily. The dose may be increased in increments of 0.5 mg or less, administered twice daily."

Hepatic adjustment

  • For severe hepatic impairment (10-15 points on Child-Pugh), initial dose 0.5 mg twice daily.

Contraindications

  • Known hypersensitivity to risperidone
  • Known hypersensitivity to paliperidone
  • Known hypersensitivity to any excipients

Clinical pearls

  • Pediatric schizophrenia/bipolar/autism irritability dosing is age- and weight-specific in label Table 1; consult pharmacy/current label
  • Monitor for metabolic changes including weight gain, hyperglycemia, and dyslipidemia.
  • Monitor for tardive dyskinesia and Neuroleptic Malignant Syndrome.
  • Use caution when operating machinery due to potential cognitive and motor impairment.
  • Titrate slowly when initiating therapy or adjusting for enzyme inhibitors/inducers.

Source and review

  • DailyMed label (risperidone), Set ID 3261e8cf-cc6e-4011-9246-aee623ad8971, effective 2026-09-10. Last reviewed: 2026-11-11